The Impact of Provider Networks on the Co-Prescriptions of Interacting Drugs: A Claims-Based Analysis

Mei-Sing Ong (), Karen L. Olson, Laura Chadwick, Chunfu Liu and Kenneth D. Mandl
Additional contact information
Mei-Sing Ong: Boston Children’s Hospital
Karen L. Olson: Boston Children’s Hospital
Laura Chadwick: Boston Children’s Hospital
Chunfu Liu: HealthCore Inc.
Kenneth D. Mandl: Boston Children’s Hospital

Drug Safety, 2017, vol. 40, issue 3, No 8, 263-272

Abstract: Abstract Introduction Multiple provider prescribing of interacting drugs is a preventable cause of morbidity and mortality, and fragmented care is a major contributing factor. We applied social network analysis to examine the impact of provider patient-sharing networks on the risk of multiple provider prescribing of interacting drugs. Methods We performed a retrospective analysis of commercial healthcare claims (years 2008–2011), including all non-elderly adult beneficiaries (n = 88,494) and their constellation of care providers. Patient-sharing networks were derived based on shared patients, and care constellation cohesion was quantified using care density, defined as the ratio between the total number of patients shared by provider pairs and the total number of provider pairs within the care constellation around each patient. Results In our study, 2% (n = 1796) of patients were co-prescribed interacting drugs by multiple providers. Multiple provider prescribing of interacting drugs was associated with care density (odds ratio per unit increase in the natural logarithm of the value for care density 0.78; 95% confidence interval 0.74–0.83; p

Keywords: Clopidogrel; Primary Care Physician; Adverse Drug Event; Electronic Supplementary Material Table; Provider Network (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40264-016-0490-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:40:y:2017:i:3:d:10.1007_s40264-016-0490-1

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-016-0490-1

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().